Abiopharma

🔍 Burkhalter Danielle (Executive)

Company: Surgery Partners, Inc. (SGRY)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Sold 7,736 shares of Common Stock at $13.6 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,103.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 17,717 shares of Common Stock at $14.11 per share (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 54,820.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 16,363 shares of Common Stock at $14.11 per share (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 71,183.00 | transaction_form_type: 4 | Footnotes: F4
• Acquired 9,150 shares of Common Stock at $14.11 per share (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 80,333.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: Shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock on February 28, 2026 and March 2, 2026.
• F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F3: Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date.
• F4: Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the first anniversary of the Grant Date.
• F5: Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the second anniversary of the Grant Date.